Skip to main content
SpringerLink
Log in

Autologous graft-versus-host disease: immunotherapy of breast cancer after bone marrow transplantation

  • Dose-intensive therapy — applications in breast cancer (Mini-symposium)
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Clinical and laboratory evidence of a dose-response relationship has prompted the investigation of highdose therapy with bone marrow transplantation in the treatment of women with metastatic breast cancer. Remission rates are high, but only a small proportion appear durable. An antitumor effect is associated with allogeneic graft-versus-host disease (GVHD) as well as with a similar syndrome that can be induced following autologous transplantation (autologous GVHD) by treatment with cyclosporine A following marrow infusion. The clinical manipulation of autologous GVHD may increase the potency of high-dose therapy. Clinical studies indicate that autologous GVHD can be induced in women with breast cancer and can be augmented by the administration of interferon gamma. Preliminary evidence indicates associated antitumor activityin vitro.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lehnert M: Reversal of multidrug resistance in breast cancer: many more open questions than answers. Ann Oncol 4:11–13, 1993

    Google Scholar 

  2. Frei E, Canellos GP: Dose: a critical factor in cancer chemotherapy. Am J Med 69:585–594, 1980

    Google Scholar 

  3. Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368–1376, 1988

    Google Scholar 

  4. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE: High-dose chemotherapy with reinfusion of purged autologous bone marrow as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83:920–926, 1991

    Google Scholar 

  5. Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper L, Frei E: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102–110, 1992

    Google Scholar 

  6. Williams SF, Gilewski T, Mick R, Bitran JD: Highdose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 10:1743–1747, 1992

    Google Scholar 

  7. Peters WP, Ross M, Vredenburgh J, Meisenberg B, Rosner G, Marks L, Mathias B, Henderson C, Hurd D, Budman D, Norton L, Weiss RB: High-dose alkylating agents and autologous bone marrow support (ABMS) for stage II/III breast cancer involving 10 or more axillary lymph nodes (Duke and CALGB 8782) [Abstract]. Proc Am Soc Clin Oncol 58:59, 1992

    Google Scholar 

  8. Shea TC, Mason JR, Storniolo AM, Newton B, Breslin M, Mullen M, Ward D, Miller L, Christian M, Taetle R: Sequential cycles of high-dose carboplatin administration with recombinant human granulocytemacrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 10:464–473, 1992

    Google Scholar 

  9. Kennedy MJ, Armstrong DK, Huelskamp AM, Ohley K, Colvin OM, Davidson NE: Phase I study of novobiocin in conjunction with high-dose alkylating agents and marrow reinfusion in the treatment of advanced breast cancer [Abstract]. Breast Cancer Res Treat 23:12A, 1992

    Google Scholar 

  10. Gale RP, Champlin RE: How does bone marrow transplantation cure leukaemia? Lancet ii:28–30, 1984

    Google Scholar 

  11. Jones RJ, Ambinder RF, Piantadosi S, Santos GW: Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649–653, 1991

    Google Scholar 

  12. Kersey JH, Weisdorf D, Nesbit ME, LeBien TW, Woods WG, McGlave PB, Kim T, Vallera DA, Goldman AI, Bostrom B, Hurd D, Ramsay NKC: Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N Engl J Med 317:461–467, 1987

    Google Scholar 

  13. Weiden PL, Sullivan KM, Fluornoy N, Storb R, Thomas ED: Antileukemic effect of graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529–1533, 1980

    Google Scholar 

  14. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner D, Storb R: Antileukemic effect of graftversus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 300:1068–1073, 1979

    Google Scholar 

  15. Santos GW: Effect of graft-versus-host disease on a spontaneous adenocarcinoma in mice. Exp Hematol 20: 46–48, 1970

    Google Scholar 

  16. Fefer A: Immunotherapy of primary Moloney sarcoma virus-induced tumors. Int J Cancer 5:327–332, 1970

    Google Scholar 

  17. Zuk JA, Walker RA: HLA class II sublocus expression in benign and malignant breast epithelium. J Pathol 155:301–309, 1988

    Google Scholar 

  18. Gastl G, Marth C, Leiter E, Gattringer C, Mayer I, Daxenbichler G, Flener R, Huber C: Effects of human recombinant alpha-2 arg-interferon and gammainterferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression. Cancer Res 45:2957–2961, 1985

    Google Scholar 

  19. Foon KA, Todd RF III: Immunologic classification of leukemia and lymphoma. Blood 68:1–31, 1986

    Google Scholar 

  20. Rappeport J, Reinherz E, Mihm M, Lopansri S, Parkman R: Acute graft-versus-host disease in recipients of bone-marrow transplants from identical twin donors. Lancet ii:717–720, 1979

    Google Scholar 

  21. Glazier AD, Tutschka PJ, Farmer ER, Santos GW: Graft-versus-host disease in cyclosporine A-treated rats following syngeneic and autologous bone marrow reconstitution. J Exp Med 158:1–8, 1983

    Google Scholar 

  22. Beschorner WE, Shinn CA, Fischer AC, Santos GW, Hess AD: Cyclosporine-induced pseudo graft-versushost disease in the early post cyclosporine period [Abstract]. Transplantation 46(Suppl 1):1125, 1988

    Google Scholar 

  23. Hess AD, Jones RJ, Morris LE, Noga SJ, Vogelsang GB, Santos GW: Autologous graft-versus-host disease: a novel approach for antitumor immunotherapy. Hum Immunol 34:219–224, 1992

    Google Scholar 

  24. Hess AD, Horwitz L, Beschorner WE, Santos GW: Development of graft-versus-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. J Exp Med 161:718–730, 1985

    Google Scholar 

  25. Sorokin K, Kimura H, Schroeder K, Wilson DH, Elison DB: Cyclosporine-induced autoimmunity: conditions for expressing disease, requirements for intact thymus, and potency estimates of autoimmune lymphocytes in drug-treated rats. J Exp Med 164:1615–1625, 1986

    Google Scholar 

  26. Geller RB, Esa AH, Beschorner WE, Frondoza CG, Santos GW, Hess AD: Successful in vitro graft-versustumor effect against Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 74:1165–1171, 1989

    Google Scholar 

  27. Noga SJ, Horwitz L, Kim H, Laulis MK, Hess AD: Interferon-gamma potentiates the anti-tumor effect of cyclosporine-induced autoimmunity. J Hematother 1:75–84, 1992

    Google Scholar 

  28. Jones RJ, Vogelsang GB, Hess AD, Farmer ER, Mann R, Geller RB, Piantadosi S, Santos GW: Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet i:754–757, 1989

    Google Scholar 

  29. Jones RJ, Vogelsang GB, Ambinder RF, Santos GW, Hess AD: Autologous marrow transplantation (ABMT) with cyclosporine (CSA)-induced autologous graftversus-host disease (GVHD) for relapsed aggressive non-Hodgkins lymphoma (NHL) [Abstract]. Blood 78:287, 1991

    Google Scholar 

  30. Yeager AM, Vogelsang GB, Jones RJ, Farmer ER, Altomonte V, Hess AD, Santos GW: Induction of cutaneous graft-versus-host reaction by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 79:3031–3035, 1992

    Google Scholar 

  31. Dale BM, Atkinson K, Kotasek D, Biggs JC, Sage RE: Cyclosporine-induced graft-versus-host disease in two patients receiving syngeneic bone marrow transplants. Transplant Proc 21:3816–3817, 1989

    Google Scholar 

  32. Carella AM, Gaozza E, Congiu A, Carlier P, Nati S, Truini M, Castellaneta A, Viale M: Cyclosporineinduced graft-versus-host disease after autologous marrow transplantation in hematological malignancies. Ann Hematol 62:156–159, 1991

    Google Scholar 

  33. Bernard D, Maurizis J-C, Ruse F, Chassagne J, Chollet P, Sauvezie B, De Latour M, Plagne R: Presence of HLA-D/DR antigens on the membrane of breast tumor cells. Clin Exp Immunol 56:215–221, 1984

    Google Scholar 

  34. Natali PG, Giacomini P, Bigotti A, Imai K, Nicotra MR, Ng AK, Ferrone S: Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res 43:660–668, 1983

    Google Scholar 

  35. Kennedy MJ, Vogelsang GB, Beveridge RA, Farmer ER, Altomonte V, Huelskamp AM, Davidson NE: Phase I trial of intravenous cyclosporine to induce graftversus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 11:478–484, 1993

    Google Scholar 

  36. Pober JS, Gimbrone MA, Cotran RS, Reiss CS, Burakoff SJ, Fiers W, Ault KA: Ia expression by vascular endothelium is inducible by activated T cells and by human gamma-interferon. J Exp Med 157:1339–1353, 1983

    Google Scholar 

  37. Schwartz R, Momburg F, Moldenhauer G, Dörken B, Schirrmacher V: Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-gamma. Int J Cancer 35:245–250, 1985

    Google Scholar 

  38. Maluish AE, Urba WJ, Longo DL, Overton WR, Coggin D, Crisp ER, Williams R, Sherwin SA, Gordon K, Steis RG: The determination of an immunologically active dose of interferon in patients with melanoma. J Clin Oncol 6:434–445, 1988

    Google Scholar 

  39. Kennedy MJ, Vogelsang G, Morris L, Farmer E, Noga SJ, Davidson NE: Phase I study of gamma-interferon to augment cyclosporine A induced graft-versus-host disease following high-dose chemotherapy with autologous marrow reinfusion for metastatic breast cancer [Abstract]. Proc Am Soc Clin Oncol 11:23, 1992

    Google Scholar 

  40. Morris LE, Vogelsang GB, Bright EC, Jones RJ, Santos GW, Hess AD: Immune reconstitution in cyclosporine A-induced autologous graft-versus-host disease [Abstract]. Blood 80:534, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology 137, The Johns Hopkins Oncology Center, 600 N. Wolfe Street, 21287-8936, Baltimore, MD, USA

    M. John Kennedy & Richard J. Jones

Authors
  1. M. John Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard J. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Held in conjunction with the 15th Annual San Antonio Breast Cancer Symposium, December 1992, and supported by an educational grant from Lederle Oncology; editing by The Medicine Group USA, Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kennedy, M.J., Jones, R.J. Autologous graft-versus-host disease: immunotherapy of breast cancer after bone marrow transplantation. Breast Cancer Res Tr 26, S31–S40 (1993). https://doi.org/10.1007/BF00668358

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00668358

Key words

Search

Navigation